Transcriptional control of the melanoma malignant phenotype

Cancer Biology and Therapy

Volumn 7, Issue 7, 2008, Pages 997-1003

  Melnikova, Vladislava O ^a   Bar Eli, Menashe ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

AP 2 ; ATF1; ATF2; CREB; Melanoma; Metastasis; NF B

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 1; ACTIVATING TRANSCRIPTION FACTOR 2; BINDING PROTEIN; CYCLIC AMP; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL;

CANCER CONTROL; CARCINOGENICITY; CELL ADHESION; DEREGULATION; DISEASE COURSE; DNA BINDING; HUMAN; MELANOMA; METASTASIS; ONCOGENE; PHENOTYPE; REVIEW; UPREGULATION;

EID: 47949122939     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.7.6535     Document Type: Review

References (130)

1. Fidler IJ. Critical determinants of metastasis. Semin Cancer Biol 2002; 12:89-96.
2. Fidler IJ, Kim SJ, Langley RR. The role of the organ microenvironment in the biology and therapy of cancer metastasis. J Cell Biochem 2007; 101:927-36.
3. de Braud F, Khayat D, Kroon BB, et al. Malignant melanoma. Crit Rev Oncol Hematol 2003; 47:35-63.
4. Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med 2006; 355:51-65.
5. Crowson AN, Magro C, Miller A, et al. The molecular basis of melanomagenesis and the metastatic phenotype. Semin Oncol 2007; 34:476-90.
6. Fountain JW, Bale SJ, Housman DE, et al. Genetics of melanoma. Cancer Surv 1990; 9:645-71.
7. Daniotti M, Oggionni M, Ranzani T, et al. BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene 2004; 23:5968-77.
8. Benjamin CL, Melnikova VO, Ananthaswamy HN. Models and mechanisms in malignant melanoma. Mol Carcinog 2007; 46:671-8.
9. INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma. Cancer Res 1996; 56:5023-32.
10. Piccinin S, Doglioni C, Maestro R, et al. p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression. Int J Cancer 1997; 74:26-30.
11. Haluska FG, Hodi FS. Molecular genetics of familial cutaneous melanoma. J Clin Oncol 1998; 16:670-82.
12. Monzon J, Liu L, Brill H, et al. CDKN2A mutations in multiple primary melanomas. N Engl J Med 1998; 338:879-87.
13. Bishop DT, Demenais F, Goldstein AM, et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 2002; 94:894-903.
14. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-54.
15. Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002; 62:6997-7000.
16. Tuveson DA, Weber BL, Herlyn M. BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell 2003; 4:95-8.
17. Yazdi AS, Palmedo G, Flaig MJ, et al. Mutations of the BRAF gene in benign and malignant melanocytic lesions. J Invest Dermatol 2003; 121:1160-2.
18. Uribe P, Wistuba II, Gonzalez S. BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin. Am J Dermatopathol 2003; 25:365-70.
19. Michaloglou C, Vredeveld LC, Soengas MS, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005; 436:720-4.
20. Gorden A, Osman I, Gai W, et al. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res 2003; 63:3955-7.
21. Omholt K, Karsberg S, Platz A, et al. Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression. Clin Cancer Res 2002; 8:3468-74.
22. Sala E, Mologni L, Truffa S, et al. BRAF Silencing by Short Hairpin RNA or Chemical Blockade by PLX4032 Leads to Different Responses in Melanoma and Thyroid Carcinoma Cells. Mol Cancer Res 2008; 6:751-9.
23. Liang S, Sharma A, Peng HH, et al. Targeting mutant (V600E) B-Raf in melanoma interrupts immunoediting of leukocyte functions and melanoma extravasation. Cancer Res 2007; 67:5814-20.
24. Lyons JF, Wilhelm S, Hibner B, et al. Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 2001; 8:219-25.
25. Haluska F, Pemberton T, Ibrahim N, et al. The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors and potential applications. Semin Oncol 2007; 34:546-54.
26. Smalley KS, Haass NK, Brafford PA, et al. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 2006; 5:1136-44.
27. Weinstein IB, Joe A. Oncogene addiction. Cancer Res 2008; 68:3077-80.
28. Nyormoi O, Bar-Eli M. Transcriptional regulation of metastasis-related genes in human melanoma. Clin Exp Metastasis 2003; 20:251-63.
29. Leslie MC, Bar-Eli M. Regulation of gene expression in melanoma: new approaches for treatment. J Cell Biochem 2005; 94:25-38.
30. Barsky SH, Sternlicht MD, Safarians S, et al. Evidence of a dominant transcriptional pathway which regulates an undifferentiated and complete metastatic phenotype. Oncogene 1997; 15:2077-91.
31. Baldi A, Santini D, Battista T, et al. Expression of AP-2 transcription factor and of its downstream target genes c-kit, E-cadherin and p21 in human cutaneous melanoma. J Cell Biochem 2001; 83:364-72.
32. Jean D, Gershenwald JE, Huang S, et al. Loss of AP-2 results in upregulation of MCAM/ MUC18 and an increase in tumor growth and metastasis of human melanoma cells. J Biol Chem 1998; 273:16501-8.
33. Tellez CS, Davis DW, Prieto VG, et al. Quantitative analysis of melanocytic tissue array reveals inverse correlation between activator protein-2alpha and protease-activated receptor-1 expression during melanoma progression. J Invest Dermatol 2007; 127:387-93.
34. Tellez C, McCarty M, Ruiz M, et al. Loss of activator protein-2alpha results in overexpression of protease-activated receptor-1 and correlates with the malignant phenotype of human melanoma. J Biol Chem 2003; 278:46632-42.
35. Bohm M, Moellmann G, Cheng E, et al. Identification of p90RSK as the probable CREB-Ser133 kinase in human melanocytes. Cell Growth Differ 1995; 6:291-302.
36. Rutberg SE, Goldstein IM, Yang YM, et al. Expression and transcriptional activity of AP-1, CRE and URE binding proteins in B16 mouse melanoma subclones. Mol Carcinog 1994; 10:82-7.
37. Poser I, Bosserhoff AK. Transcription factors involved in development and progression of malignant melanoma. Histol Histopathol 2004; 19:173-88.
38. Bhoumik A, Gangi L, Ronai Z. Inhibition of melanoma growth and metastasis by ATF2-derived peptides. Cancer Res 2004; 64:8222-30.
39. Berger AJ, Kluger HM, Li N, et al. Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Res 2003; 63:8103-7.
40. Vannini I, Bonafe M, Tesei A, et al. Short interfering RNA directed against the SLUG gene increases cell death induction in human melanoma cell lines exposed to cisplatin and fotemustine. Cell Oncol 2007; 29:279-87.
41. Poser I, Dominguez D, de Herreros AG, et al. Loss of E-cadherin expression in melanoma cells involves upregulation of the transcriptional repressor Snail. J Biol Chem 2001; 276:24661-6.
42. Lenhard V, Doerr W, Kuhner A, et al. [Letter: Retro-orbital fibrosis in Ormond's disease]. Dtsch Med Wochenschr 1975; 100:1255.
43. Gupta PB, Kuperwasser C, Brunet JP, et al. The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat Genet 2005; 37:1047-54.
44. Huang S, DeGuzman A, Bucana CD, et al. Nuclear factor-kappaB activity correlates with growth, angiogenesis and metastasis of human melanoma cells in nude mice. Clin Cancer Res 2000; 6:2573-81.
45. Krasilnikov M, Ivanov VN, Dong J, et al. ERK and PI3K negatively regulate STAT-transcriptional activities in human melanoma cells: implications towards sensitization to apoptosis. Oncogene 2003; 22:4092-101.
46. Niu G, Bowman T, Huang M, et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 2002; 21:7001-10.
47. Mirmohammadsadegh A, Hassan M, Bardenheuer W, et al. STAT5 phosphorylation in malignant melanoma is important for survival and is mediated through SRC and JAK1 kinases. J Invest Dermatol 2006; 126:2272-80.
48. Johnson JP. Cell adhesion molecules in the development and progression of malignant melanoma. Cancer Metastasis Rev 1999; 18:345-57.
49. McGary EC, Lev DC, Bar-Eli M. Cellular adhesion pathways and metastatic potential of human melanoma. Cancer Biol Ther 2002; 1:459-65.
50. Melnikova VO, Bar-Eli M. Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8. Pigment Cell Res 2006; 19:395-405.
51. Hsu MY, Wheelock MJ, Johnson KR, et al. Shifts in cadherin profiles between human normal melanocytes and melanomas. J Investig Dermatol Symp Proc 1996; 1:188-94.
52. Danen EH, de Vries TJ, Morandini R, et al. E-cadherin expression in human melanoma. Melanoma Res 1996; 6:127-31.
53. Mortarini R, Anichini A. From adhesion to signalling: roles of integrins in the biology of human melanoma. Melanoma Res 1993; 3:87-97.
54. Danen EH, Van Muijen GN, Ruiter DJ. Role of integrins as signal transducing cell adhesion molecules in human cutaneous melanoma. Cancer Surv 1995; 24:43-65.
55. Lehmann JM, Holzmann B, Breitbart EW, et al. Discrimination between benign and malignant cells of melanocytic lineage by two novel antigens, a glycoprotein with a molecular weight of 113,000 and a protein with a molecular weight of 76,000. Cancer Res 1987; 47:841-5.
56. Thies A, Moll I, Berger J, et al. CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. J Clin Oncol 2002; 20:2530-6.
57. Hofmann UB, Westphal JR, Van Muijen GN, et al. Matrix metalloproteinases in human melanoma. J Invest Dermatol 2000; 115:337-44.
58. Hofmann UB, Westphal JR, Zendman AJ, et al. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression. J Pathol 2000; 191:245-56.
59. Vaisanen A, Tuominen H, Kallioinen M, et al. Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value. J Pathol 1996; 180:283-9.
60. Singh RK, Gutman M, Radinsky R, et al. Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res 1994; 54:3242-7.
61. Singh RK, Varney ML, Bucana CD, et al. Expression of interleukin-8 in primary and metastatic malignant melanoma of the skin. Melanoma Res 1999; 9:383-7.
62. Varney ML, Johansson SL, Singh RK. Distinct expression of CXCL8 and its receptors CXCR1 and CXCR2 and their association with vessel density and aggressiveness in malignant melanoma. Am J Clin Pathol 2006; 125:209-16.
63. Joshi M, Strandhoy J, White WL. Nitric oxide synthase activity is upregulated in melanoma cell lines: a potential mechanism for metastases formation. Melanoma Res 1996; 6:121-6.
64. Ekmekcioglu S, Ellerhorst J, Smid CM, et al. Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. Clin Cancer Res 2000; 6:4768-75.
65. Huang S, Jean D, Luca M, et al. Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis. Embo J 1998; 17:4358-69.
66. Zhang J, Williams T. Identification and regulation of tissue-specific cis-acting elements associated with the human AP-2alpha gene. Dev Dyn 2003; 228:194-207.
67. Williams T, Admon A, Luscher B, et al. Cloning and expression of AP-2, a cell-type-specific transcription factor that activates inducible enhancer elements. Genes Dev 1988; 2:1557-69.
68. Imagawa M, Chiu R, Karin M. Transcription factor AP-2 mediates induction by two different signal-transduction pathways: protein kinase C and cAMP. Cell 1987; 51:251-60.
69. Schorle H, Meier P, Buchert M, et al. Transcription factor AP-2 essential for cranial closure and craniofacial development. Nature 1996; 381:235-8.
70. Luscher B, Mitchell PJ, Williams T, et al. Regulation of transcription factor AP-2 by the morphogen retinoic acid and by second messengers. Genes Dev 1989; 3:1507-17.
71. WAF1/CIP1 expression. Nat Genet 1997; 15:78-82.
72. Batsche E, Muchardt C, Behrens J, et al. RB and c-Myc activate expression of the E-cadherin gene in epithelial cells through interaction with transcription factor AP-2. Mol Cell Biol 1998; 18:3647-58.
73. Li H, Watts GS, Oshiro MM, et al. AP-2alpha and AP-2gamma are transcriptional targets of p53 in human breast carcinoma cells. Oncogene 2006; 25:5405-15.
74. Berger AJ, Davis DW, Tellez C, et al. Automated quantitative analysis of activator protein-2-alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction. Cancer Res 2005; 65:11185-92.
75. Gershenwald JE, Sumner W, Calderone T, et al. Dominant-negative transcription factor AP-2 augments SB-2 melanoma tumor growth in vivo. Oncogene 2001; 20:3363-75.
76. Shih IM, Elder DE, Speicher D, et al. Isolation and functional characterization of the A32 melanoma-associated antigen. Cancer Res 1994; 54:2514-20.
77. Ellis HA, Peart KM. Iliac bone marrow mast cells in relation to the renal osteodystrophy of patients treated by haemodialysis. J Clin Pathol 1976; 29:502-16.
78. Luca M, Hunt B, Bucana CD, et al. Direct correlation between MUC18 expression and metastatic potential of human melanoma cells. Melanoma Res 1993; 3:35-41.
79. Shih IM, Elder DE, Hsu MY, et al. Regulation of Mel-CAM/MUC18 expression on melanocytes of different stages of tumor progression by normal keratinocytes. Am J Pathol 1994; 145:837-45.
80. Xie S, Luca M, Huang S, et al. Expression of MCAM/MUC18 by human melanoma cells leads to increased tumor growth and metastasis. Cancer Res 1997; 57:2295-303.
81. Mills L, Tellez C, Huang S, et al. Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Res 2002; 62:5106-14.
82. Even-Ram S, Uziely B, Cohen P, et al. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med 1998; 4:909-14.
83. Nierodzik ML, Chen K, Takeshita K, et al. Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis. Blood 1998; 92:3694-700.
84. Tellez C, Bar-Eli M. Role and regulation of the thrombin receptor (PAR-1) in human melanoma. Oncogene 2003; 22:3130-7.
85. Nierodzik ML, Karpatkin S. Thrombin induces tumor growth, metastasis and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 2006; 10:355-62.
86. Wojtukiewicz MZ, Tang DG, Ben-Josef E, et al. Solid tumor cells express functional "tethered ligand" thrombin receptor. Cancer Res 1995; 55:698-704.
87. Zacharski LR, Memoli VA, Morain WD, et al. Cellular localization of enzymatically active thrombin in intact human tissues by hirudin binding. Thromb Haemost 1995; 73:793-7.
88. Grand RJ, Turnell AS, Grabham PW. Cellular consequences of thrombin-receptor activation. Biochem J 1996; 313:353-68.
89. Macfarlane SR, Seatter MJ, Kanke T, et al. Proteinase-activated receptors. Pharmacol Rev 2001; 53:245-82.
90. Zucker S, Conner C, DiMassmo BI, et al. Thrombin induces the activation of progelatinase A in vascular endothelial cells. Physiologic regulation of angiogenesis. J Biol Chem 1995; 270:23730-8.
91. Yoshida E, Verrusio EN, Mihara H, et al. Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin. Cancer Res 1994; 54:3300-4.
92. Yoshida S, Ono M, Shono T, et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 1997; 17:4015-23.
93. Luca M, Huang S, Gershenwald JE, et al. Expression of interleukin-8 by human melanoma cells upregulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol 1997; 151:1105-13.
94. Huang S, Mills L, Mian B, et al. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth and metastasis of human melanoma. Am J Pathol 2002; 161:125-34.
95. Lopez-Otin C, Matrisian LM. Emerging roles of proteases in tumour suppression. Nat Rev Cancer 2007; 7:800-8.
96. Natali PG, Nicotra MR, Digiesi G, et al. Expression of gp185HER-2 in human cutaneous melanoma: implications for experimental immunotherapeutics. Int J Cancer 1994; 56:341-6.
97. Jiang H, Su ZZ, Lin JJ, et al. The melanoma differentiation associated gene mda-7 suppresses cancer cell growth. Proc Natl Acad Sci USA 1996; 93:9160-5.
98. Descheemaeker KA, Wyns S, Nelles L, et al. Interaction of AP-1-, AP-2- and Sp1-like proteins with two distinct sites in the upstream regulatory region of the plasminogen activator inhibitor-1 gene mediates the phorbol 12-myristate 13-acetate response. J Biol Chem 1992; 267:15086-91.
99. Cowley GP, Smith ME. Cadherin expression in melanocytic naevi and malignant melanomas. J Pathol 1996; 179:183-7.
100. Werner H, Stannard B, Bach MA, et al. Cloning and characterization of the proximal promoter region of the rat insulin-like growth factor I (IGF-I) receptor gene. Biochem Biophys Res Commun 1990; 169:1021-7.
101. van den Oord JJ, Vandeghinste N, De Ley M, et al. Bcl-2 expression in human melanocytes and melanocytic tumors. Am J Pathol 1994; 145:294-300.
102. Silins G, Grimmond S, Egerton M, et al. Analysis of the promoter region of the human VEGF-related factor gene. Biochem Biophys Res Commun 1997; 230:413-8.
103. Gille J, Swerlick RA, Caughman SW. Transforming growth factor-alpha-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2-dependent DNA binding and transactivation. Embo J 1997; 16:750-9.
104. Xie S, Price JE, Luca M, et al. Dominant-negative CREB inhibits tumor growth and metastasis of human melanoma cells. Oncogene 1997; 15:2069-75.
105. Jean D, Harbison M, McConkey DJ, et al. CREB and its associated proteins act as survival factors for human melanoma cells. J Biol Chem 1998; 273:24884-90.
106. Jean D, Tellez C, Huang S, et al. Inhibition of tumor growth and metastasis of human melanoma by intracellular anti-ATF-1 single chain Fv fragment. Oncogene 2000; 19:2721-30.
107. Melnikova VO, Mourad-Zeidan AA, Lev DC, et al. Platelet-activating factor mediates MMP-2 expression and activation via phosphorylation of cAMP-response element-binding protein and contributes to melanoma metastasis. J Biol Chem 2006; 281:2911-22.
108. Bhoumik A, Ivanov V, Ronai Z. Activating transcription factor 2-derived peptides alter resistance of human tumor cell lines to ultraviolet irradiation and chemical treatment. Clin Cancer Res 2001; 7:331-42.
109. Gupta S, Campbell D, Derijard B, et al. Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science 1995; 267:389-93.
110. Kaszubska W, Hooft van Huijsduijnen R, Ghersa P, et al. Cyclic AMP-independent ATF family members interact with NFkappaB and function in the activation of the E-selectin promoter in response to cytokines. Mol Cell Biol 1993; 13:7180-90.
111. Kim SJ, Wagner S, Liu F, et al. Retinoblastoma gene product activates expression of the human TGFbeta2 gene through transcription factor ATF-2. Nature 1992; 358:331-4.
112. Shimizu M, Nomura Y, Suzuki H, et al. Activation of the rat cyclin A promoter by ATF2 and Jun family members and its suppression by ATF4. Exp Cell Res 1998; 239:93-103.
113. Tsai EY, Jain J, Pesavento PA, et al. Tumor necrosis factor alpha gene regulation in activated T cells involves ATF-2/Jun and NFATp. Mol Cell Biol 1996; 16:459-67.
114. Ivanov VN, Ronai Z. Downregulation of tumor necrosis factor alpha expression by activating transcription factor 2 increases UVC-induced apoptosis of late-stage melanoma cells. J Biol Chem 1999; 274:14079-89.
115. Ivanov VN, Ronai Z. p38 protects human melanoma cells from UV-induced apoptosis through downregulation of NFkappaB activity and Fas expression. Oncogene 2000; 19:3003-12.
116. Batlle E, Sancho E, Franci C, et al. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2000; 2:84-9.
117. Cano A, Perez-Moreno MA, Rodrigo I, et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000; 2:76-83.
118. Arlt A, Schafer H. NFkappaB-dependent chemoresistance in solid tumors. Int J Clin Pharmacol Ther 2002; 40:336-47.
119. Dhawan P, Singh AB, Ellis DL, et al. Constitutive activation of Akt/protein kinase B in melanoma leads to upregulation of nuclear factor-kappaB and tumor progression. Cancer Res 2002; 62:7335-42.
120. Rodolfo M, Daniotti M, Vallacchi V. Genetic progression of metastatic melanoma. Cancer Lett 2004; 214:133-47.
121. Ivanov VN, Fodstad O, Ronai Z. Expression of ring finger-deleted TRAF2 sensitizes metastatic melanoma cells to apoptosis via upregulation of p38, TNFalpha and suppression of NFkappaB activities. Oncogene 2001; 20:2243-53.
122. Ihle JN. The Stat family in cytokine signaling. Curr Opin Cell Biol 2001; 13:211-7.
123. Mertens C, Darnell JE Jr. SnapShot: JAK-STAT signaling. Cell 2007; 131:612.
124. Bowman T, Garcia R, Turkson J, et al. STATs in oncogenesis. Oncogene 2000; 19:2474-88.
125. Hirano T, Nakajima K, Hibi M. Signaling mechanisms through gp130: a model of the cytokine system. Cytokine Growth Factor Rev 1997; 8:241-52.
126. Kirschen D, Flom MC. Monocular central-field occlusion for intractable diplopia. Am J Optom Physiol Opt 1977; 54:325-31.
127. Turkson J, Bowman T, Garcia R, et al. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol 1998; 18:2545-52.
128. Chin H, Arai A, Wakao H, et al. Lyn physically associates with the erythropoietin receptor and may play a role in activation of the Stat5 pathway. Blood 1998; 91:3734-45.
129. Lund TC, Coleman C, Horvath E, et al. The Src-family kinase Lck can induce STAT3 phosphorylation and DNA binding activity. Cell Signal 1999; 11:789-96.
130. Merritt WM, Lin YG, Spannuth WA, et al. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst 2008; 100:359-72.